We are passionate about accelerated drug development pathways
Delivering new value to patients with unmet needs.
Be Part of the JourneyWhat We Strive For
OrchestratePharma is pioneering DRPx innovation to bring effective treatments to market faster, safer, and at a fraction of traditional costs.
DRPx Innovation
Drug Repurposing (DRPx) leverages existing approved drugs with known safety profiles to develop new treatments faster and at lower cost.
Fexofenadine Platform
Our portfolio is built around fexofenadine, a well-characterized molecule with untapped therapeutic potential across multiple indications.
Patient-First Approach
Every program is designed to deliver meaningful outcomes for patients with unmet medical needs.
Latest News
OP2101 - OrchestratePharma initiates phase 1 bioavailability study with IVRS
OrchestratePharma has initiated its phase 1 bioavailability study with IVRS, marking a significant milestone in the development of OP2101.
OrchestratePharma signs agreement with Cellix Bioscience for CSU
OrchestratePharma has signed an agreement with Cellix Bioscience to advance the clinical development of fexofenadine-based treatments for chronic spontaneous urticaria.
Our Science
We are unlocking the untapped potential of fexofenadine — a molecule with a proven safety record and remarkable versatility across dermatological and inflammatory conditions.
Explore Our ScienceOur Portfolio
Our product portfolio is focused on fexofenadine, encompassing 6 drug concepts covering up to 12 indications with a high therapeutic index.
View FexoTopicBe Part of the Journey
Are you a patient, doctor, inventor or investor? Follow us or join us on the journey to bring new treatments to those who need them most.
Contact Us